Atrás
45
41
25
Rango del Día
$18.61
$18.61
Rango de 52 Semanas
$8.62
$20.78
Volumen
200
Promedio 50D / 200D
$17.91
/
$13.07
Cierre Anterior
$18.53
Historial de Precios
Tendencias Financieras
Comparación con Pares
vs mediana del sector Healthcare (626 pares)
| Métrica | Acción | Mediana del Sector |
|---|---|---|
| P/E | 18.2 | 0.4 |
| P/B | 4.7 | 2.9 |
| ROE % | 38.8 | 3.8 |
| Net Margin % | 5.8 | 3.9 |
| Rev Growth 5Y % | 9.2 | 10.0 |
| D/E | 0.9 | 0.2 |
Puntos Clave
Revenue grew 9.19% annually over 5 years — modest growth
Earnings grew 28.41% over the past year
ROE of 38.83% indicates high profitability
Generating 63.35M in free cash flow
PEG of 0.83 suggests growth is underpriced
Revenue growth is accelerating — 1Y growth exceeds 5Y average by 3.96%
Crecimiento
Revenue Growth (5Y)
9.19%
Revenue (1Y)13.15%
Earnings (1Y)28.41%
FCF Growth (3Y)N/A
Calidad
Return on Equity
38.83%
ROIC14.49%
Net Margin5.82%
Op. Margin8.33%
Seguridad
Debt / Equity
0.92
Current Ratio1.37
Interest Coverage7.20
Valoración
P/E Ratio
18.20
P/B Ratio4.71
EV/EBITDA12.67
Dividend Yield0.02%
All Fundamental Metrics
| Growth | |||
| Revenue Growth (1Y) | 13.15% | Revenue Growth (3Y) | 12.75% |
| Earnings Growth (1Y) | 28.41% | Earnings Growth (3Y) | 68.58% |
| Revenue Growth (5Y) | 9.19% | Earnings Growth (5Y) | 70.22% |
| Profitability | |||
| Revenue (TTM) | 1.66B | Net Income (TTM) | 96.58M |
| ROE | 38.83% | ROA | 9.06% |
| Gross Margin | 12.02% | Operating Margin | 8.33% |
| Net Margin | 5.82% | Free Cash Flow (TTM) | 63.35M |
| ROIC | 14.49% | FCF Growth (3Y) | N/A |
| Safety | |||
| Debt / Equity | 0.92 | Current Ratio | 1.37 |
| Interest Coverage | 7.20 | Dividend Yield | 0.02% |
| Valuation | |||
| P/E Ratio | 18.20 | P/B Ratio | 4.71 |
| P/S Ratio | 1.06 | PEG Ratio | 0.83 |
| EV/EBITDA | 12.67 | Dividend Yield | 0.02% |
| Market Cap | 1.76B | Enterprise Value | 1.75B |
Income Statement
Annual, most recent first
| Metric | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 |
|---|---|---|---|---|---|
| Revenue | 1.66B | 1.47B | 1.30B | 1.22B | 1.17B |
| Net Income | 96.58M | 75.21M | 33.98M | 69.55M | 11.50M |
| EPS (Diluted) | 1.11 | 0.86 | 0.40 | -0.05 | 0.11 |
| Gross Profit | 199.43M | 1.47B | 167.62M | 76.83M | 115.61M |
| Operating Income | 138.25M | 111.21M | 111.79M | 20.99M | 63.18M |
Balance Sheet
Annual, most recent first
| Metric | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 |
|---|---|---|---|---|---|
| Total Assets | 1.07B | 719.79M | 672.73M | 781.58M | 900.32M |
| Total Liabilities | 692.58M | 595.44M | 584.81M | 680.88M | 798.40M |
| Shareholders' Equity | 373.07M | 124.35M | 87.92M | 100.70M | 101.92M |
| Total Debt | 342.65M | 292.49M | 334.52M | 383.97M | 536.85M |
| Cash & Equivalents | 348.90M | 121.85M | 75.18M | 167.28M | 104.63M |
| Current Assets | 451.57M | 243.70M | 187.14M | 258.04M | 224.92M |
| Current Liabilities | 329.91M | 292.88M | 226.39M | 274.99M | 281.91M |
Puntuaciones de Estrategias
This stock passed the criteria for 3 strategies
Score = fit strength (0–100)
Rank = position among all matches
Growth + Value
Growth at a Reasonable Price (Peter Lynch)
#205 of 326
Custom
Balanced Risk
#106 of 148
Custom
Lower Risk
#131 of 136
Actividad Reciente
Entró
Growth at a Reasonable Price (Peter Lynch)
Mar 24, 2026
Entró
Balanced Risk
Mar 24, 2026
Entró
Lower Risk
Mar 24, 2026